Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice

Gene Therapy

Volumn 5, Issue 8, 1998, Pages 1130-1136

  Cao, X ^a   Ju, D W ^a   Tao, Q ^a   Wang, J ^a   Wan, T ^a   Wang, B M ^a   Zhang, W ^a   Hamada, H ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Foundation for the Promotion of Cancer Research (Japan)   (Japan)

Author keywords

Adenovirus; Cytosine deaminase; Gene therapy; Granulocyte macrophage colony stimulating factor; Melanoma; Suicide gene

Indexed keywords

CD8 ANTIGEN; CYTOSINE DEAMINASE; FLUCYTOSINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DENDRITIC CELL; DNA TRANSFECTION; GENE TRANSFER; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; T LYMPHOCYTE; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALIA; ESCHERICHIA COLI; MURINAE;

EID: 0031659433     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300727     Document Type: Article

References (44)

1. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Therapy 1995; 2: 235-244.
2. Mullen CA. Metabolic suicide genes in gene therapy. Pharmac Ther 1994; 63: 199-207.
3. Tiberghien P. Use of suicide genes in gene therapy. J Leukocyte Biol 1994; 56: 203-209.
4. Kwong YL et al. Adenoviral mediated suicide gene therapy for hepatic metastases of breast cancer. Cancer Gene Ther 1996; 3: 339-344.
5. Izquierdo M et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Therapy 1996; 3: 491-495.
6. Dilber MS et al. Suicide gene therapy for plasma cell tumors. Blood 1996; 88: 2192-2200.
7. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wildtype tumor. Cancer Res 1994; 54: 1503-1506.
8. Austin EA, Huber BE. A first step in development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 1992; 43: 380-387.
9. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-37.
10. Hirschowitz EA et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995; 6: 1055-1063.
11. Szala S, Missol E, Sochanik A, Strozyk M. The use of cationic liposomes C CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors. Gene Therapy 1996; 3: 1026-1031.
12. Huber BE et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase Cancer Res 1993; 53: 4619-4626.
13. Huber BE et al. Metabolism of 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302-8306.
14. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4351.
15. Consalvo M et al. 5-Fluorocytosine induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995; 154: 5302-5312.
16. Ju DW, Cao X, Acres B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model. Cancer Gene Ther 1997; 4: 139-144.
17. Anderson WF. Gene therapy for cancer. Hum Gene Ther 1994; 5: 1-2.
18. Cao X et al. Enhanced efficacy of combination of IL-2 gene and IL-6 gene transfected tumor cells in the treatment of established metastatic tumors. Gene Therapy 1996; 3: 421-426.
19. Cao X et al. Induction of antitumor immunity and treatment of preestablished tumors by inactivated IL-6 gene transfected melanoma cells combined with low dose IL-2. J Cancer Res Clin Oncol 1995; 121. 721-728.
20. Cao X et al. Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon-α gene therapy in combination with adoptive chemoimmunotherapy. J Cancer Res Clin Oncol 1995; 121: 457-462.
21. Abe J et al. Antitumor effect induced by granulocyte/ macrophage colony-stimulating factor gene-modified tumor vaccination' comparison of adenovirus- and retrovirusmediated genetic transduction. J Cancer Res Clin Oncol 1995; 121: 587-593.
22. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
23. Muyombwe A, Olivier M, Ouellette M, Papadopoulou B. Selective killing of Leishmania amastigotes expressing a thymidine kinase suicide gene. Exp Parasitol 1997; 85: 35-42.
24. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-784.
25. Barinaga M. Gene therapy for clogged arteries passes test in pigs. Science 1994; 265: 738-741.
26. Rogers RP et al. Killing Epstein-Barr virus positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther 1996; 7: 2235-2245.
27. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8- 73-85.
28. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor specific gene therapy. Hum Gene Ther 1995; 6: 881-893.
29. Ring CJ, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Therapy 1996; 3: 1094-1103.
30. Harris JD et al. Gene therapy for cancer using tumor-specific prodrug activation. Gene Therapy 1994; 1: 170-175.
31. Klatzmann D. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum Gene Ther 1996; 7: 255-267.
32. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide gene therapy. Lancet 1997; 349: 2-3.
33. Ishii-Morita H et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Therapy 1997; 4: 244-251.
34. Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
35. Chen SH et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56: 3758-3762.
36. Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res 1996; 56: 1361-1366.
37. Santodonato L et al. Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 1996; 7: 1-10.
38. Gabilovich DI et al. Dendritic cells in antitumor immune response. II. Dendritic cells grown from bone marrow precursors but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996; 170: 111-119.
39. Lee C-K et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997; 8: 187-193.
40. Armstrong CA et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996; 56: 2191-2198.
41. Inaba K et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocytemacrophage colony-stimulating factor. J Exp Med 1992; 176: 1693-1702.
42. Ramesh R et al. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 1996; 3: 373-384
43. Pitts JD. Cancer gene therapy: a bystander effect using the gap junction pathway. Mol Carcinogen 1994; 11: 127-130.
44. Kanai F et al. In vivo gene therapy for alpha fetoprotein producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57: 461-465.